SEED Entered into Strategic Research Collaboration with Eisai and Closed First Round of Series A Financing in August 2024.
SEED Achieved 3rd Milestone with Lilly R&D Collaboration in March 2024.
SEED Discloses Novel Molecular Glue IND Candidate at “TPD Think Tank” Symposium.
SEED Therapeutics’ Mission
To break through the scientific barriers to discovering Molecular Glues for effective therapy and cures for the world’s most debilitating diseases and disorders.
Collaborating with an unparalleled team of world-leading experts in the Ubiquitin Proteasome System and the field of Targeted Protein Degradation. SEED Therapeutics is advancing its groundbreaking Molecular Glues discovery platform for the treatment of multiple indications, including cancer, neurodegradation, and infectious diseases.
DRUG DISCOVERY
SEED Therapeutics: A focus on Molecular Glues
SEED Therapeutics is a global research company uniquely focused on harnessing and engineering molecules that use Molecular Glues to attack protein targets previously believed to be ”undruggable.”
PIPELINE
THE TEAM
Click below to learn more about SEED Therapeutics’ leadership
NEWSROOM
SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025 Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models;...
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago Two PROTAC synergy using two E3 ligases for achieving levels of degradation of...
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors King of Prussia, PA – January 28,...
Nature: Protein degraders push into novel target space
info@seedtherapeutics.com info@seedtherapeutics.com PUBLICATIONS Nature: Protein degraders push into novel target space Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory.
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head...
Events
“Targeted Protein Degradation Think Tank” Symposium
PARTNERS
CAREERS
Make a difference in improving human health
CONTACT US
Investor Contact: IR@seedtherapeutics.com
Media Contact: PR@seedtherapeutics.com
General Inquires: info@seedtherapeutics.com